Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from ATAI Life Sciences

A 36-year-old CEO saw how psychedelics treated his best friend’s mental illness. Now his Peter Thiel-funded firm wants to bring the drugs to the masses

Florian Brand's Atai Life Sciences went public three years after launching, fueled by Silicon Valley interest and promising science, but it's still waiting for its first big breakthrough.

Fortune

Atai's New MDMA-Based EMP-01 Compound Moves Forward To The Clinical Stage

Atai Life Sciences' (NASDAQ: ATAI) wholly-owned subsidiary EmpathBio has received Medsafe central regulatory and the Health and Disability Ethics Committees (HDEC) approvals to begin participant enrollment in its Phase 1 trial of proprietary MDMA-based drug EMP-01

Benzinga

Psychedelic Stock Gainers And Losers From June 22, 2022

GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 4.17% at $3.50

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

ATAI Life Sciences, Compass Pathways Among Top Psychedelic Movers Of Today

GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 1.06% at $0.81 LOSERS:

Benzinga

Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today

GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 9.47% at $0.72

Benzinga

ATAI Life Sciences, Mind Medicine Among Top Psychedelic Movers Of Today

GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 3.55% at $0.36

Benzinga

ATAI Life Sciences, Intelgenx Technologies Among Top Psychedelic Movers Of Today

GAINERS: Field Trip Health (NASDAQ:FTRP) shares closed up 7.05% at $0.91

Benzinga

Read news from The Economist, FT, and more,
with one subscription

atai Life Sciences: Unparalleled Diversification With 10 Psychedelic Compounds Going Into Clinical Trials In 2022

In the speculative world of ‘psychedelic’ biotech, companies that are under-capitalized or lacking pipeline diversity face an uphill battle to reach the finish line.

Benzinga

Christian Angermayer Bullish On Psychedelic Sector And Life Extension Technology

In this week’s Trade To Black Podcast, TDR Founder Shadd Dales and lead financial writer Benjamin A. Smith interview the founder of Apeiron Investment Group, Christian Angermayer.

Benzinga

Psychedelics Atai Life Sciences: Optimizing Drug Development By Avoiding Big Pharma's Past Missteps

In the early days of the psychedelics industry, financial reports mean very little. Unless a company wildly misses its operating spending budget and hemorrhages cash by more than expected, the report is basically a synopsis of a given company’s highlights and milestones over the previous quarter.

Benzinga

Atai Life Sciences Posts Earnings for Q1 2022, Advancing Key Milestones In Psychedelic Drug Development

Atai Life Sciences (NASDAQ: ATAI), a biotech company leading the development of psychedelic compounds for mental health purposes, issued its financial report for the first quarter of the year, ended March 31, 2022.

Benzinga

Field Trip Health, ATAI Life Sciences Among Top Psychedelic Movers Of Today

GAINERS: Field Trip Health (NASDAQ:FTRP) shares closed up 20.93% at $0.94

Benzinga

Psychedelic Stock Gainers And Losers From May 9, 2022

GAINERS: LOSERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed down 13.47% at $3.34

Benzinga

Allied, ATAI Life Sciences Among Top Psychedelic Movers Of Today

GAINERS: Allied (OTC:ALID) shares closed up 5.27% at $0.76

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

ATAI Life Sciences, Compass Pathways Among Top Psychedelic Movers Of Today

GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 3.97% at $4.97

Benzinga

Psychedelic Stock Gainers And Losers From April 14, 2022

GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 2.50% at $5.32

Benzinga

Christian Angermayer Buys 1 Million Shares Of Atai Life, His Own Company

Christian Angermayer, founder and chairman of Atai Life Sciences (NASDAQ:ATAI), told Twitter that he bought 1 million shares of his company. “Many #biotech stocks are cheap at the moment. In my opinion, Atai Life Sciences AG stands out though for two reasons: the size of the market (unfortunately) the fact…

Benzinga

ATAI Life Sciences's Return On Capital Employed Insights

ATAI Life Sciences (NASDAQ:ATAI) brought in sales totaling $230.00 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 194.78%, resulting in a loss of $93.27 million.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results

atai Life Sciences N.V. (NASDAQ:ATAI) has announced its financial results for the fourth quarter and full year ended December 31, 2021. 2021 Financial Results Highlights included: Positive Phase 2b data with COMP360 from a ground-breaking treatment-resistant depression (TRD) trial, highly encouraging Phase 2a proof-of-mechanism data with RL-007 in cognitive impairment…

Benzinga

Psychedelic Stock Gainers And Losers From March 29, 2022

GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 9.05% at $5.42

Benzinga

Psychedelic Stock Gainers And Losers From March 9, 2022

GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 10.32% at $5.56

Benzinga

Mind Medicine, Cybin Among Top Psychedelic Movers Of Today

GAINERS: Revive Therapeutics (OTC: RVVTF) shares closed up 2.51% at $0.22 LOSERS: Mind Medicine (NASDAQ: MNMD) shares closed down 8.09% at $1.25 Cybin (AMEX:CYBN) shares closed down 6.25% at $1.05 ATAI Life SciencesGAINERS:

Benzinga

Psychedelic Stock Gainers And Losers From February 9, 2022

GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 14.29% at $5.76

Benzinga

ATAI Life Sciences, Mind Medicine Among Top Psychedelic Movers Of Today

GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 7.89% at $5.33

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.